The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47%.

The study's primary endpoint was to evaluate the efficacy of bremelanotide combined with tirzepatide in reducing body weight. Data from this trial are expected later this quarter. The results from ...

Now, as the companies run trials to flesh out the potential of the drugs to treat other conditions, an observational study from Washington ... Eli Lilly, after tirzepatide's late-stage cardio ...